RLFTF was hit hard yesterday, no mortality benefit

RLFTF was hit hard yesterday, no mortality benefit. HGEN share price is down, I can't remember where their trials are, but both the above are given by IV. FDA should be anxious to approve Leronlimab, which also can be a shot actually administered eventually at home. That alone is a huge benefit, add pristine safety and our eIND results and Dr Patterson and andecdotal cases.

If leveraged and coordinating shorting was outlawed, CYDY would be at about $15 IMO today, regardless, it will be there very soon.